Combining data on the bioavailability of midazolam and physiologically-based pharmacokinetic modeling to investigate intestinal CYP3A4 ontogeny.
Journal
CPT: pharmacometrics & systems pharmacology
ISSN: 2163-8306
Titre abrégé: CPT Pharmacometrics Syst Pharmacol
Pays: United States
ID NLM: 101580011
Informations de publication
Date de publication:
26 Jun 2024
26 Jun 2024
Historique:
revised:
06
06
2024
received:
01
02
2024
accepted:
11
06
2024
medline:
26
6
2024
pubmed:
26
6
2024
entrez:
26
6
2024
Statut:
aheadofprint
Résumé
Pediatric physiologically-based modeling in drug development has grown in the past decade and optimizing the underlying systems parameters is important in relation to overall performance. In this study, variation of clinical oral bioavailability of midazolam as a function of age is used to assess the underlying ontogeny models for intestinal CYP3A4. Data on midazolam bioavailability in adults and children and different ontogeny patterns for intestinal CYP3A4 were first collected from the literature. A pediatric PBPK model was then used to assess six different ontogeny models in predicting bioavailability from preterm neonates to adults. The average fold error ranged from 0.7 to 1.38, with the rank order of least to most biased model being No Ontogeny < Upreti = Johnson < Goelen < Chen < Kiss. The absolute average fold error ranged from 1.17 to 1.64 with the rank order of most to least precise being Johnson > Upreti > No Ontogeny > Goelen > Kiss > Chen. The optimal ontogeny model is difficult to discern when considering the possible influence of CYP3A5 and other population variability; however, this study suggests that from term neonates and older a faster onset Johnson model with a lower fraction at birth may be close to this. For inclusion in other PBPK models, independent verification will be needed to confirm these results. Further research is needed in this area both in terms of age-related changes in midazolam and similar drug bioavailability and intestinal CYP3A4 ontogeny.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Certara UK Limited and The Author(s). CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Johnson TN, Small BG, Rowland YK. Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations. CPT Pharmacometrics Syst Pharmacol. 2020;11:373‐383.
Zhang X, Yang Y, Grimstein M, et al. Application of PBPK Modeling and simulation for regulatory decision making and its impact on US prescribing information: an update on the 2018–2019 submissions to the US FDA's Office of Clinical Pharmacology. J Clin Pharmacol. 2020;60(Suppl 1):S160‐S178.
Verscheijden LFM, Koenderink JB, Johnson TN, de Wildt SN, Russel FGM. Physiologically‐based pharmacokinetic models for children: starting to reach maturation? Pharmacol Ther. 2020;211:107541.
Johnson TN, Tucker GT, Tanner MS, Rostami‐Hodjegan A. Changes in liver volume from birth to adulthood: a meta‐analysis. Liver Transpl. 2005;11:1481‐1493.
Maharaj AR, Gonzalez D, Cohen‐Wolkowiez M, Hornik CP, Edginton AN. Improving Pediatric protein binding estimates: an evaluation of alpha1‐acid glycoprotein maturation in healthy and infected subjects. Clin Pharmacokinet. 2018;57:577‐589.
Emoto C, Johnson TN, Neuhoff S, Hahn D, Vinks AA, Fukuda T. PBPK model of morphine incorporating developmental changes in hepatic OCT1 and UGT2B7 proteins to explain the variability in clearances in neonates and Small infants. CPT Pharmacometrics Syst Pharmacol. 2018;7:464‐473.
Villiger A, Stillhart C, Parrott N, Kuentz M. Using physiologically based pharmacokinetic (PBPK) modelling to gain insights into the effect of physiological factors on Oral absorption in paediatric populations. AAPS J. 2016;18:933‐947.
Johnson TN, Jamei M, Rowland‐Yeo K. How does in vivo biliary elimination of drugs change with age? Evidence from in vitro and clinical data using a systems pharmacology approach. Drug Metab Dispos. 2016;44:1090‐1098.
Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS. Identification of glucocorticoid‐inducible cytochromes P‐450 in the intestinal mucosa of rats and man. J Clin Invest. 1987;80:1029‐1036.
Paine MF, Khalighi M, Fisher JM, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A‐dependent metabolism. J Pharmacol Exp Ther. 1997;283:1552‐1562.
Paine MF, Shen DD, Kunze KL, et al. First‐pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther. 1996;60:14‐24.
Lown KS, Kolars JC, Thummel JL, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos. 1994;22:947‐955.
Chen YT, Trzoss L, Yang D, Yan B. Ontogenic expression of human carboxylesterase‐2 and cytochrome P450 3A4 in liver and duodenum: postnatal surge and organ‐dependent regulation. Toxicology. 2015;330:55‐61.
Fakhoury M, Litalien C, Medard Y, et al. Localization and mRNA expression of CYP3A and P‐glycoprotein in human duodenum as a function of age. Drug Metab Dispos. 2005;33:1603‐1607.
Johnson TN, Tanner MS, Taylor CJ, Tucker GT. Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis. Br J Clin Pharmacol. 2001;51:451‐460.
Goelen J, Farrell J, McGeehan J, et al. Quantification of drug metabolising enzymes and transporter proteins in the paediatric duodenum via LC‐MS/MS proteomics using a QconCAT technique. Eur J Pharm Biopharm. 2023;191:68‐77.
Kiss M, Mbasu R, Nicolai J, et al. Ontogeny of small intestinal drug transporters and metabolizing enzymes based on targeted quantitative proteomics. Drug Metab Dispos. 2021;49:1038‐1046.
Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383‐391.
Johnson TN, Howgate EM, de Wildt SN, Turner MA, Rowland YK. Use of developmental midazolam and 1‐Hydroxymidazolam data with Pediatric physiologically based Modeling to assess cytochrome P450 3A4 and uridine diphosphate Glucuronosyl transferase 2B4 ontogeny in vivo. Drug Metab Dispos. 2023;51:1035‐1045.
Codaccioni M, Southall RL, Dinh J, Johnson TN. Prediction of pediatric pharmacokinetics for CYP3A4 metabolized drugs: comparison of the performance of two hepatic ontogeny within a physiologically based pharmacokinetic model. J Clin Pharmacol. 2024; (in press) DOI 10.1002/jcph2452.
Upreti VV, Wahlstrom JL. Meta‐analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling. J Clin Pharmacol. 2016;56:266‐283.
Salem F, Johnson TN, Abduljalil K, Tucker GT, Rostami‐Hodjegan A. A re‐evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data. Clin Pharmacokinet. 2014;53:625‐636.
Van der Veken M, Brouwers J, Ozbey AC, et al. Investigating tacrolimus disposition in paediatric patients with a physiologically based pharmacokinetic model incorporating CYP3A4 ontogeny, mechanistic absorption and red blood cell binding. Pharmaceutics. 2023;15:2231. doi:10.3390/pharmaceutics15092231
Stevens JC, Hines RN, Gu C, et al. Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther. 2003;307:573‐582.
Rostami‐Hodjegan A, Tucker G. ‘In silico’ simulations to assess the ‘in vivo’ consequences of ‘in vitro’ metabolic drug‐drug interactions. Drug Discov Today Technol. 2004;1:441‐448.
Johnson TN, Bonner JJ, Tucker GT, Turner DB, Jamei M. Development and applications of a physiologically‐based model of paediatric oral drug absorption. Eur J Pharm Sci. 2018;115:57‐67.
de Wildt SN, Kearns GL, Hop WC, et al. Pharmacokinetics and metabolism of oral midazolam in preterm infants. Br J Clin Pharmacol. 2002;53:390‐392.
Brussee JM, Yu H, Krekels EHJ, et al. First‐pass CYP3A‐mediated metabolism of midazolam in the Gut Wall and liver in preterm neonates. CPT Pharmacometrics Syst Pharmacol. 2018;7:374‐383.
Abduljalil K, Pan X, Pansari A, Jamei M, Johnson TN. A preterm physiologically based pharmacokinetic model. Part I: physiological parameters and model building. Clin Pharmacokinet. 2020;59:485‐500.
Johnson TN, Boussery K, Rowland‐Yeo K, Tucker GT, Rostami‐Hodjegan A. A semi‐mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet. 2010;49:189‐206.
Maharaj AR, Wu H, Hornik CP, et al. Use of normalized prediction distribution errors for assessing population physiologically based pharmacokinetic model adequacy. J Pharmacokinet Pharmacodyn. 2020;47:199‐218.
Kharasch ED, Walker A, Isoherranen N, et al. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther. 2007;82:410‐426.
Kvitne KE, Drevland OM, Haugli N, et al. Intraindividual variability in absolute bioavailability and clearance of midazolam in healthy individuals. Clin Pharmacokinet. 2023;62:981‐987.
Payne K, Mattheyse FJ, Liebenberg D, Dawes T. The pharmacokinetics of midazolam in paediatric patients. Eur J Clin Pharmacol. 1989;37:267‐272.
Reed MD, Rodarte A, Blumer JL, et al. The single‐dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration. J Clin Pharmacol. 2001;41:1359‐1369.
van Groen BD, Krekels EHJ, Mooij MG, et al. The oral bioavailability and metabolism of midazolam in stable critically ill children: a pharmacokinetic microtracing study. Clin Pharmacol Ther. 2021;109:140‐149.
Vet NJ, Brussee JM, de Hoog M, et al. Inflammation and organ failure severely affect midazolam clearance in critically ill children. Am J Respir Crit Care Med. 2016;194:58‐66.
Brussee JM, Yu H, Krekels EHJ, et al. Characterization of intestinal and hepatic CYP3A‐mediated metabolism of midazolam in children using a physiological population pharmacokinetic modelling approach. Pharm Res. 2018;35:182.
von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivistö KT. Cytochrome P450 3A4 and P‐glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther. 2004;75:172‐183.
de Waal T, Handin N, Brouwers J, et al. Expression of intestinal drug transporters and metabolic enzymes in neonatal and pediatric patients. Int J Pharm. 2024;654:123962.
Dinh J, Johnson TN, Grimstein M, Lewis T. Physiologically based pharmacokinetics modeling in the neonatal population‐current advances, challenges, and opportunities. Pharmaceutics. 2023;15:2579. doi:10.3390/pharmaceutics15112579
Jamei M, Turner D, Yang J, et al. Population‐based mechanistic prediction of oral drug absorption. AAPS J. 2009;11:225‐237.
Heimbach T, Lin W, Hourcade‐Potelleret F, et al. Physiologically based pharmacokinetic model to supplement nilotinib pharmacokinetics and confrom dose selection in pediatric patients. J Pharm Sci. 2019;108:2191‐2198.
Cleary Y, Gertz M, Grimsey P, et al. Model‐based drug–drug interaction extrapolation strategy from adults to children: risdiplam in pediatric patients with spinal muscular atrophy. Clin Pharmacol Ther. 2021;110:1547‐1557.
Zhou W, Johnson TN, Bui KH, et al. Predictive performance of physiologically based pharmacokinetic (PBPK) modeling of drugs extensively metabolized by major cytochrome P450s in children. Clin Pharmacol Ther. 2018;104:188‐200.
Lang J, Vincent L, Chenel M, Ogungbenro K, Galatin A. Impact of hepatic CYP3A4 ontogeny function on drug‐drug interaction risk in pediatric physiologically based pharmacokinetic/pharmacodynamic modeling: criteria literature review and ivabradine case study. Clin Pharmacol Ther. 2021;109:1618‐1630.
Johnson TN, Rostami‐Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 2006;45:931‐956.